bluuebunny/crossref_metadata_2025_split huggingface dataset:
Oral rinse MMP‐8 point‐of‐care immuno test identifies patients with strong periodontal inflammatory burden
Authors: Leppilahti JM , Ahonen M‐M , Hernández M , Munjal S , Netuschil L , Uitto V‐J , Sorsa T , Mäntylä P 
Published: July 2010

Oral Diseases (2010) 17, 115–122Objective:  To determine whether oral rinse matrix metalloproteinase (MMP)‐8 levels, measured by three different methods, tissue inhibitor of matrix metalloprotease‐1 (TIMP‐1) levels and elastase activity differentiate subjects with different periodontal condition; and second, to find out if MMP‐8 levels were comparable among the methods used.Methods:  MMP‐8 levels were analysed with an immunofluorometric method (IFMA), dentoELISA and commercial ELISA. Also TIMP‐1 levels and elastase activity were measured. For statistical analysis 214 study subjects were categorized into four groups, specified by the presence and number of moderate (4–5 mm) and deep (≥6 mm) periodontal pockets, and bleeding on probing percentage.Results:  MMP‐8 levels especially measured by dentoELISA and adjusted to the number of teeth per subject differentiated the study group with strong periodontal inflammatory burden from groups with lower levels. This was also verified with receiver operating characteristic (ROC) analysis. Elastase activity associated with higher IFMA and dentoELISA MMP‐8 levels. IFMA MMP‐8/TIMP and dentoELISA MMP‐8/TIMP‐1 tended to be higher with the increasing level of periodontal inflammatory burden. TIMP‐1 levels decreased with increasing age.Conclusions:  Oral rinse MMP‐8 together with TIMP‐1 analysis may have potential in complementary periodontal diagnostics. dentoELISA can be applied in quantitative oral rinse chair side biomarker diagnostics.
Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients
Authors: Jang M‐U , Park J‐W , Kho H‐S , Chung S‐C , Chung J‐W 
Published: July 2010

Oral Diseases (2011) 17, 187–193Objectives:  To investigate the level and interrelationship of nerve growth factor (NGF) and sensory neuropeptides [substance P (SP), calcitonin gene‐related peptide (CGRP)] in plasma and saliva of chronic migraine patients, and to analyze the association between pain intensity and their concentration.Materials and methods:  Plasma and resting whole saliva were collected from 33 chronic migraine patients and 36 control subjects. NGF, SP, and CGRP concentrations were measured by enzyme immunoassay and pain intensity of each subject was measured using the Graded Chronic Pain Scale.Results:  Chronic migraine patients showed higher NGF and neuropeptide levels in both plasma and saliva compared to the control subjects. Plasma NGF, and plasma and saliva levels of SP and CGRP were highly associated with pain intensity. There was a significant positive correlation between NGF and both neuropeptide levels in plasma, and between the neuropeptide levels in both plasma and saliva. Plasma levels of SP and CGRP were significantly correlated with their saliva level.Conclusions:  The increased production of NGF and sensory neuropeptides may play an important role in the maintenance of pain in chronic migraine and analysis results of human saliva could act as an index of disease state and therapeutic outcome.
THE BOOK SHELF
Authors: Bailey Franklin C. 
Published: July 2010

Books Reviewed in this Article:1. Bach, George R., and Peter Wyden. The Intimate Enemy.2. Berne, Eric. Principles of Group Treatment.3. Deutch, Ronald M. The Key to Feminine Sexual Response In Marriage.4. Lederer, William J., and Don D. Jackson. The Mirages of Marriage.5. McCary, James Leslie. Human Sexuality.6. Peterson, James A. Married Love in the Middle Years.
THE BOOK SHELF
Authors: Hulbert E. Ronald 
Published: July 2010

FAMILY ROLES AND INTERACTION: AN ANTHOLOGY Edited by Jerold HeissTEACHING MULTI‐CULTURAL POPULATIONS: FIVE HERITAGES Edited by James C. Stone & Donald P. DeNeviCURRENT PSYCHOTHERAPIES Edited by Raymond CorsiniA GUIDE TO PSYCHOLOGISTS AND THEIR CONCEPTS Vernon J. Nordby & Calvin S. Hall
THE BOOKSHELF
Authors: Hulbert E. Ronald 
Published: July 2010

THE FIRST INTERVIEW WITH THE FAMILY Helm Stierlin, lngeborg Rucker‐Embden, Norbert Wetzel and Michael Wirsching HANDBOOK OF FAMILY THERAPY Allan S. Gurman, Ph.D., and David P. Kniskern, Psy.D. HELPING COUPLES CHANGE Richard B. Stuart CREATIVE MARRIAGE: MAKING YOUR MARRIAGE WORK IN THE 80's Me1 Krantzler
THE BOOKSHELF
Authors: Hulbert E. Ronald 
Published: July 2010

Books reviewed in this article: SHARING PARENTHOOD AFTER DIVORCE Ciji Ware FOUNDATIONS OF FAMILY THERAPYLynn Hoffman Mediation of Child Custody and Visitation Disputes(Eds) Hugh Mclsaac, M.S.W. and Jeanne Ames MARITAL CRISIS AND SHORT‐TERM COUNSELING‐A CASEBOOKDorothy R. Freeman
THE BOOKSHELF
Authors: Hulbert E. Ronald 
Published: July 2010

Book Review in this article THE DIVORCE REVOLUTION: The Unexpected Social and Economic Consequences for Women and Children In America, Lenore Weitzman IN THE INTEREST OF CHILDREN: ADVOCACY, LAW REFORM, AND PUBLIC POLICY, Robert A. Burt, David L. Chambers and Michael S. Wald Stephen D. Sugarman, Franklin E. Zimring and Rayman L. Solomon
AND HOW ARE THE CHILDREN?
Authors: Bruch Carol S. 
Published: July 2010

ABSTRACTRecent innovations in American child custody law have affected both the substantive law and the procedures by which custody decisions are reached. Professor Bruch describes these developments, analyses their underpinnings in psychology and ideology, and identifies both intended and unrecognized effects of the dispute resolution process on the custody decision. She concludes that many new doctrines and procedures that have been widely assumed to benefit children, including joint custody and mediation, often disserve children's interests.
THE SECOND ANNUAL MEYER ELKIN ADDRESS
Authors: Thomson George 
Published: July 2010

A year ago, our journal had the opportunity to publish the inaugural Meyer Elkin Address by Jonah, Peter, and Marian Wright Edelman. This past summer, the Association of Family and Conciliation Courts was honored to have George Thomson speak at its conference in Vancouver, British Columbia. Thomson was presented with this honor for his hard work and dedication to family law in Canada and throughout the world. The Family and Conciliation Courts Review is honored to publish this speech by Thomson.Described by his colleagues as a “miracle worker” and “superman”, Thomson has led a fascinating career that has followed several different paths. As an undergraduate student, Thomson attained a B.A. in philosophy and English from Queen's University in Kingston, Ontario. He remained at Queen's University and received an LL.B., then completed his formal education with an LL.M. from the University of California.Thomson has had a diverse background in the legal field, serving as an educator, a judge, and a government official. From 1968 until 1971, he worked as both an associate professor and assistant dean at the University of Western Ontario in London, Ontario. After his brief stint with the university, he was appointed judge of the Provincial Court for the Province of Ontario. Thomson held this position for five years before becoming an associate deputy minister of Community and Social Services, where he served as the head of the Children's Services Division.In the 1980s, Thomson returned to the bench in the provincial court. Additionally, he was the director of education for the Law Society of Upper Canada. Most notably, however, Thomson chaired a provincial committee on social welfare reform. By 1989, Thomson had moved from the bench into governmental work. He briefly served as the deputy minister of citizenship for Ontario. He was then appointed the deputy minister of labor until 1992.From 1992 until 1994, Thomson served as Ontario's deputy attorney general. He then became the deputy minister of justice and deputy attorney general of Canada. Most recently, Thomson has been a special advisor to the minister of justice and attorney general of Canada.The following Meyer Elkin address was presented at the annual Convention of the Association of Family and Conciliation Courts in Vancouver, Canada, in June 1999.
Effect of citrus pulp silage feeding on concentration of beta‐cryptoxanthin in plasma and milk of dairy cows
Authors: TANAKA Masahito , KAMIYA Yuko , SUZUKI Tomoyuki , NAKAI Yutaka 
Published: July 2010

ABSTRACTCitrus pulp is known to contain a functional molecule of beta‐cryptoxanthin which is one of the carotenoids showing anti‐oxidative capacity. Influences of citrus pulp silage feeding to dairy cows on beta‐cryptoxanthin concentration in plasma, other blood properties and milking performances were investigated. Four Holstein cows were fed total mixed ration (TMR) containing citrus pulp silage 20% dry matter (DM) for 2 weeks with free access to the TMR. Dry mater intake, milk production and milk components 2 weeks later were not altered compared with those of the control group without citrus pulp silage. Activities of aspartate aminotransferase, alanin aminotransferase and gamma‐glutamyltranspeptidase in plasma were not affected by feeding of citrus pulp silage. Concentrations of protein, albumin, sulfhydryl residue, ascorbic acid, thio‐barbituric acid reactive substance and urea nitrogen in plasma were also not altered by citrus pulp silage feeding. Concentration of beta‐cryptoxanthin in plasma was increased approximately 20‐fold compared with the control group (P < 0.05). Content of beta‐cryptxanthin in pooled milk fat fraction was also increased approximately three times compared with that of the control group. Feeding of TMR containing citrus pulp silage 15% DM for 30 days to eight dairy cows also increased plasma beta‐cryptoxanthin concentration 30‐fold compared with that before feeding.
Efficacy and Safety of Mirodenafil in Men Taking Antihypertensive Medications
Authors: Paick Jae-Seung , Kim Je Jong , Kim Sae Chul , Moon Ki Hak , Min Kweon Sik , Park Kwangsung , Suh Jun-Kyu , Yang Dae Yul 
Published: July 2010

ABSTRACT

Introduction
Mirodenafil is a recently developed oral phosphodiesterase type 5 inhibitor, which was observed to significantly improve erectile function and was well tolerated in men with broad-spectrum erectile dysfunction (ED).

Aim
To investigate the efficacy and safety of mirodenafil treatment compared with placebo in men taking at least one antihypertensive medication.

Methods
A multicenter, double-blind, placebo-controlled, parallel group, fixed-dose study was conducted with 109 subjects who were randomized to placebo or mirodenafil 100 mg for 12 weeks on an “as needed” basis.

Main Outcome Measures
The primary efficacy measures were the changes from baseline in sum of scores on International Index of Erectile Function-erectile function domain (IIEF-EF) questions 1 to 5 and 15 with treatment. The secondary efficacy measures included scores on IIEF question 3 and 4 (Q3 and Q4), all domain scores of IIEF, and Sexual Encounter Profile Question 2 and 3 (SEP2 and SEP3) along with responses to Global Assessment Question (GAQ) and Life Satisfaction Checklist (LSC). The safety assessments included laboratory tests, vital signs, 12-lead electrocardiogram recordings, and patients’ reporting of adverse events.

Results
The mirodenafil group showed significantly greater increase in IIEF-EF scores at 12 weeks compared with the placebo group (9.35 ± 6.86 vs. 2.66 ± 6.44, P &lt;0.001). The mirodenafil group also demonstrated significantly greater improvement in scores of IIEF Q3 and Q4, other four domains of IIEF, SEP2, SEP3, and LSC along with percentages of patients responding positively to GAQ compared with the placebo group. During the study, no clinically significant changes were observed regarding blood pressure, heart rate, electrocardiographic findings, or laboratory values. Facial flushing and headache were the most common treatment-associated adverse events, which were mild or moderate in severity, resolving spontaneously.

Conclusions
Mirodenafil was effective and safe in men with ED concomitantly taking antihypertensive medications.
What is the meaning of palliative care in the Asia‐Pacific region?
Authors: O'CONNOR Margaret , O'BRIEN Anthony Paul , GRIFFITHS Debra , POON Edward , CHIN Jacqueline , PAYNE Sheila , NORDIN Rusli 
Published: July 2010

AbstractThis paper describes the preliminary work required to understand cultural differences in palliative care in the United Kingdom and three countries in the Asia‐Pacific region, in preparation for a cross‐country study. The study is intended to address cultural understandings of palliative care, the role of the family in end of life care, what constitutes good care and the ethical issues in each country. Suggestions are then made to shape the scope of the study and to be considered as outcomes to improve care of the dying in these countries. It is anticipated that the method used to achieve consensus on cross‐country palliative care issues will be both qualitative and quantitative. Identifying key priorities in the delivery and quality measures of palliative care will involve participants in focus groups, a Delphi survey and in the development of clinical indicators towards creating standards of palliative care common to the Asian Pacific region.
It Ain't Broke: The Past, Present, and Future of Venture Capital
Authors: Kaplan Steven N. , Lerner Josh 
Published: July 2010

This article presents a selective history of the U.S. venture capital (VC) industry, a discussion of the current state of the market, and some predictions about where the market is going. There is no doubt that the U.S. venture capital industry has been very successful. The VC model has provided an efficient solution to a difficult problem—that of enabling people with promising ideas but often limited track records to raise capital from outside investors. A large fraction of IPOs, including many of the most successful, have been funded by venture capitalists, and the U.S. VC model has been copied around the world.Armed with this historical perspective, the authors view with skepticism the recent claims that the VC model is broken. In the past, VC investments in companies have represented a remarkably constant 0.15% of the total value of the stock market; and commitments to VC funds, while more variable, have been consistently in the 0.10% to 0.20% range. Both of these percentages have continued to hold in recent years. And despite the relatively low number of IPOs, the returns to VC funds this decade have largely maintained their historical relationship to the overall stock market.To be sure, VC investment and returns continue to be subject to boom‐and‐bust cycles. But if the recent period has most of the features of a bust, the authors view today's historically low level of commitments to U.S. VC funds as a fairly reliable indicator of relatively high expected returns for the 2009 and (probably) 2010 vintage years. Perhaps the most promising future role for venture capital, as the authors suggest in closing, is to increase the productivity of the corporate research and development function through various kinds of partnerships and outsourcing arrangements.
Protection from Inflammation, Immunosuppression and Carcinogenesis Induced by UV Radiation in Mice by Topical Pycnogenol®¶
Authors: Sime Suzann , Reeve Vivienne E. 
Published: July 2010

ABSTRACTPycnogenol® is a standardized extract of the bark of the French maritime pine, Pinus pinaster Ait., that has multiple biological effects, including antioxidant, anti‐inflammatory and anticarcinogenic properties. This study describes the effect of topical application of lotions containing Pycnogenol® to Skh:hr hairless mice undergoing minimally inflammatory daily exposures to solar‐simulated UV radiation (SSUV). We report that concentrations of Pycnogenol® of 0.05–0.2% applied to the irradiated dorsal skin immediately after exposure resulted in dose‐dependent reduction of the inflammatory sunburn reaction, measured as its edema component. When mice received three consecutive daily exposures of minimally edematous SSUV, their ability to raise a contact hypersensitivity (CHS) reaction was suppressed by 54%. Pycnogenol® lotions applied postirradiation reduced this immunosuppression to 22% (0.05% Pycnogenol®) and 13% (0.1 % Pycnogenol®). Furthermore, when CHS was suppressed by 71% with exogenous treatment with cis‐urocanic acid, the putative epidermal mediator of photoimmunosuppression, 0.2% Pycnogenol® lotion reduced the immunosuppression to 18%. Chronic exposure to SSUW on 5 days/week for 10 weeks induced skin tumors from 11 weeks in both control mice and in mice receiving daily applications of 0.05% Pycnogenol®, but tumor appearance was significantly delayed until 20 weeks in mice receiving 0.2% Pycnogenol®. Furthermore, whereas 100% of control mice had at least one tumor by 30 weeks, and mice treated with 0.05% Pycnogenol® by 33 weeks, the maximum tumor prevalence in mice treated with 0.2% Pycnogenol® was significantly reduced to 85%, with some mice remaining tumor free. Average tumor multiplicity was also significantly reduced by 0.2% Pycnogenol®, from 5.2 in control mice to 3.5 at 35 weeks. Thus, topical Pycnogenol® offered significant and dose‐dependent protection from SSUV induced acute inflammation, immunosuppression and carcinogenesis, when applied to the skin after daily irradiation. Pycnogenol®, therefore, in addition to its recognized health benefits in other organs, appears to have potential in providing photoprotection for humans in a complementary role with sunscreens, having demonstrable activity when applied to the skin after, rather than before, UV exposure.
Calculation of Singlet Oxygen Dose from Photosensitizer Fluorescence and Photobleaching During mTHPC Photodynamic Therapy of MLL Cells¶
Authors: Dysart Jonathan S. , Singh Gurmit , Patterson Michael S. 
Published: July 2010

ABSTRACTPredicting the therapeutic outcome of photodynamic therapy (PDT) requires knowledge of the amount of cytoxic species generated. An implicit approach to assessing PDT efficacy has been proposed where changes in photosensitizer (PS) fluorescence during treatment are used to predict treatment outcome. To investigate this,in vitroexperiments were performed in which Mat‐LyLu cells were incubated inmeta‐tetra(hydroxyphenyl)chlorin (mTHPC) and then irradiated with 652 nm light. PS concentration, fluence rate and oxygenation were independently controlled and monitored during the treatment. Fluorescence of mTHPC was monitored during treatment and, at selected fluence levels, cell viability was determined using a colony‐formation assay. Singlet oxygen dose was calculated using four different models and was compared with cell survival. For the dose metric based on singlet oxygen–mediated PS photobleaching, a universal relationship between cell survival and singlet oxygen dose was found for all treatment parameters. Analysis of the concentration dependence of bleaching suggests that the lifetime of singlet oxygen within the cell is 0.05–0.25 μs. Generation of about 9 × 108molecules of singlet oxygen per cell reduces the surviving fraction by 1/e.
A study of atypical APTT derivative curves on the ACL TOP coagulation analyser
Authors: SOLANO C. , ZERAFA P. , BIRD R. 
Published: July 2010

SummaryIntroduction:  The graphical representation of clotting data can provide useful information. A novel feature of the ACL TOP software allows display of clot reaction curves with superimposed first and second derivative curves. We noted atypical derivative plots associated with normal ‘S’‐shaped clot reaction curves in some abnormal activated partial thromboplastin time (APTT).Methods:  We tested 179 citrate plasmas with four different APTT reagents on the ACL TOP. We documented the prevalence and utility of these APTT atypical derivative curves in these patients.Results:  Ellagic acid APTT reagents commonly produce atypical derivative curves despite normal ‘S’‐shaped clot reaction curves. Occasionally, these atypical second derivative curves may cause incorrect APTT results. With silica activator APTT reagents, atypical derivative curves were associated with genuine coagulation abnormalities such as single factor deficiencies and lupus anticoagulants (LAs). To our knowledge, this novel finding has not been reported.Conclusion:  Atypical derivative curves seen in ellagic acid APTTs are of limited diagnostic use because of the frequency with which they occur. This may be related to the need to optimize the data reduction utilized on the ACL TOP for these reagents. With silica activator APTTs, the presence of atypical derivative curves proved to be a very simple tool when troubleshooting unexpected abnormal APTT results, commonly predicting a factor deficiency or LA that would warrant further investigation. The cause of these aberrant derivative curves is probably related to abnormal thrombin generation in the APTT test and warrants further study.
Hyponatremia in Heart Failure: The Role of Arginine Vasopressin and Its Antagonism
Authors: Rosner Mitchell H. , Ronco Claudio 
Published: July 2010

Congest Heart Fail.2010;16(4)(suppl 1):S7–S14.©2010 Wiley Periodicals, Inc.Heart failure (HF) is associated with substantial cost, morbidity, and mortality. One of the common complications associated with HF, as well as with its treatment, is the development of hyponatremia. Hyponatremia is due to the nonosmotic release of arginine vasopressin (AVP) along with neurohormonal activation of the renin‐angiotensin‐aldosterone and sympathetic nervous systems. Hyponatremia in patients with HF is associated with poor outcomes and can limit the use of diuretic therapy. Given that AVP is the primary stimulus for the development of hyponatremia in these patients, therapies that target AVP action would seem a logical choice in the therapeutic regimen for HF. Drugs that antagonize the action of AVP at the vasopressin V2receptor, which is primarily responsible for water resorption in the kidney, are now available and have been studied in patients with HF. These drugs (termedvaptans) have been associated with improvements in serum sodium concentration, urine output, body weight, and mental functioning but have shown no long‐term mortality benefit in patients with HF. The role of vaptans in the HF armament will require further studies that center on the proper timing and indications for their use as well as their cost‐efficacy.
Copeptin: A Biomarker of Cardiovascular and Renal Function
Authors: Morgenthaler Nils G. 
Published: July 2010

Congest Heart Fail. 2010;16(4)(suppl 1):S37–S44.©2010 Wiley Periodicals, Inc.Arginine vasopressin (AVP or antidiuretic hormone) is one of the key hormones in the human body responsible for a variety of cardiovascular and renal functions. It has so far escaped introduction into the routine clinical laboratory due to technical difficulties and preanalytical errors. Copeptin, the C‐terminal part of the AVP precursor peptide, was found to be a stable and sensitive surrogate marker for AVP release. Copeptin behaves in a similar manner to mature AVP in the circulation, with respect to osmotic stimuli and hypotension. During the past years, copeptin measurement has been shown to be of interest in a variety of clinical indications, including cardiovascular diseases such as heart failure, myocardial infarction, and stroke. This review summarizes the recent progress on the diagnostic use of copeptin in cardiovascular and renal diseases and discusses the potential use of copeptin measurement in the context of therapeutic interventions with vasopressin receptor antagonists.